CONMED (NYSE: CNMD – Get Rating) and Hyperfine (NASDAQ: HYPR – Get Rating) are both medical companies, but which is the best investment? We will compare the two companies based on their risk strength, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability.
Risk and Volatility
CONMED has a beta of 1.53, indicating its stock price is 53% more volatile than the S&P 500. In comparison, Hyperfine has a beta of 0.82, indicating its stock price is 18% less volatile than the S&P 500.
Insider and Institutional Ownership
22.7% of Hyperfine shares are held by institutional investors. 1.1% of CONMED shares are held by company insiders. Strong institutional ownership indicates that endowments, hedge funds, and large money managers believe a stock is poised for long-term growth.
Profitability
This table compares the net margins, return on equity and return on assets of CONMED and Hyperfine.
| Net margins | Return on equity | return on assets | |
| CONMED | 6.19% | 13.20% | 5.66% |
| Hyperfine | N / A | -59.73% | -26.18% |
Analyst Notes
This is a summary of recent recommendations for CONMED and Hyperfine, as provided by MarketBeat.com.
| Sales Ratings | Hold odds | Buy reviews | Strong buy odds | Rating | |
| CONMED | 0 | 1 | 3 | 0 | 2.75 |
| Hyperfine | 0 | 0 | 1 | 0 | 3.00 |
CONMED currently has a consensus price target of $161.67, suggesting a potential upside of 43.77%. Hyperfine has a consensus price target of $8.00, suggesting a potential upside of 168.46%. Given Hyperfine’s stronger consensus rating and higher likely upside, analysts clearly believe Hyperfine is more favorable than CONMED.
Valuation and benefits
This chart compares the revenue, earnings per share (EPS), and valuation of CONMED and Hyperfine.
| Gross revenue | Price/sales ratio | Net revenue | Earnings per share | Price/earnings ratio | |
| CONMED | $1.01 billion | 3.29 | $62.54 million | $1.94 | 57.96 |
| Hyperfine | $1.50 million | 139.72 | -$64.85 million | N / A | N / A |
CONMED has higher revenues and profits than Hyperfine.
Summary
CONMED beats Hyperfine on 8 out of 12 factors compared between the two stocks.
CONMED Company Profile (Get an assessment)
CONMED Corporation, a medical technology company, develops, manufactures and sells surgical devices and related equipment for surgical procedures worldwide. It offers orthopedic surgery products, including TruShot with Y-Knot all-in-one soft tissue fixation system, Y-knot suture anchors and PopLok knotless suture anchors, which provide unique clinical solutions to orthopedic surgeons for soft tissue repair. injuries, as well as support products that allow surgeons to perform minimally invasive sports medicine surgeries. The company markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept and Shutt brands. It also offers general surgery products, such as clinical insufflation, smoke evacuation, electrosurgery and endomechanics products; and endoscopic technologies, including diagnostic and therapeutic products used in gastroenterology procedures and products for the treatment of diseases of the biliary structures, as well as cardiac monitoring products including ECG and EEG electrodes and defibrillation electrodes cardiac. The company markets its products directly to hospitals, surgical centers and other healthcare facilities, as well as through specialty medical distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.
Hyperfine Company Profile (Get an assessment)
Hyperfine, Inc. provides imaging, monitoring and magnetic resonance imaging products. It offers the Swoop portable MRI imaging system to address an unmet need for point-of-care medical imaging through a combination of hardware and software services. The company was incorporated in 2014 and is based in Guilford, Connecticut.
Get news and reviews for CONMED Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for CONMED and related companies with MarketBeat.com’s FREE daily newsletter.
